Market Herald logo

Subscribe

Be the first with the news that moves the market

Biotech company Paradigm Pharmaceuticals has launched a $77.9 million capital raise.

The raise will invest in further clinical research, drug development and hiring US-based million staff. $51.6 million of the raise will comprise of placement to investors across Australia.

This placement will consist of an issue of 34,370,099 shares. The remaining $26.3m will go to an accelerated non-renounceable entitlement offer underwritten by Bell Potter securities.

The entitlement offer will consist of 17,537,431 shares at A$1.50 per share. This raise will put the company in a strong position to negotiate commercial transactions.

The company is currently researching osteoarthritis (OA) and mucopolysaccharidosis (MPS) treatment. MPS is a rare condition where the patient is unable to break down sugar molecules throughout the body.

Both OA and MPS research projects are currently in stage three. Current OA research shows possible remission of disease and reduction of pain.

Please see the announcement attached

PAR by the numbers
More From The Market Herald
The Market Herald Video

" Security Matters (ASX:SMX) enters into $2m standby equity facility

Security Matters (ASX:SMX) has entered into a standby equity deed with Evolution Capital.
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
The Market Herald Video

" Archer Materials (ASX:AXE) secures Hong Kong patent for quantum computing chip

Archer Materials (ASX:AXE) announces the grant of a Hong Kong patent for its 12CQ quantum computing…